Agenda coming soon.

The program combines lively, debate-style exchanges with focused didactic lectures, creating a dynamic educational experience that both challenges current practice and reinforces evidence-based management strategies across hematologic malignancies.

In leukemia, discussions will highlight molecular and genomic risk stratification, biomarker integration, and adaptive therapeutic strategies for optimizing outcomes across disease settings.

The lymphoma block will explore novel antibody platforms, cellular and immune-based therapies, and response-adapted approaches that are reshaping the treatment landscape and improving durability of remission.

The myeloma sessions will focus on immune innovations, bispecific antibodies, and next-generation transplant strategies, emphasizing personalized treatment pathways and integration of real-world evidence into clinical practice.

Across all sessions, the hallmark debate-centered format fosters meaningful exchange, expert interpretation of emerging data, and practical insights to advance outcomes in hematologic malignancies.